"Liquid Biopsy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Obtaining material for pathological examination and analysis, from bodily fluids. Material retrieved includes CELL-FREE NUCLEIC ACIDS; CELL-DERIVED MICROPARTICLES; EXOSOMES; CIRCULATING NEOPLASM CELLS; and other circulating cells and CELLULAR STRUCTURES.
| Descriptor ID |
D000073890
|
| MeSH Number(s) |
E01.370.225.500.384.100.396 E01.370.225.998.054.396 E05.200.500.384.100.396 E05.200.998.054.396 E05.242.384.100.396
|
| Concept/Terms |
Liquid Biopsy- Liquid Biopsy
- Biopsies, Liquid
- Biopsy, Liquid
- Liquid Biopsies
|
Below are MeSH descriptors whose meaning is more general than "Liquid Biopsy".
Below are MeSH descriptors whose meaning is more specific than "Liquid Biopsy".
This graph shows the total number of publications written about "Liquid Biopsy" by people in this website by year, and whether "Liquid Biopsy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 7 | 9 |
| 2018 | 7 | 12 | 19 |
| 2019 | 2 | 5 | 7 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Liquid Biopsy" by people in Profiles.
-
Sensitive detection of anti-spike antibodies enables improved understanding of SARS-CoV-2 pathogenesis. Immunology. 2021 09; 164(1):1-2.
-
Identification of Lung and Blood Microbiota Implicated in COVID-19 Prognosis. Cells. 2021 06 10; 10(6).
-
COVID-19 "Liquid Biopsy" Could Offer Monitoring, Prognostic Tool. JAMA. 2021 Mar 09; 325(10):924.
-
Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points. RNA Biol. 2021 05; 18(5):688-695.
-
Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis. J Biomech. 2021 03 05; 117:110235.
-
Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals. Expert Rev Mol Diagn. 2021 01; 21(1):101-107.
-
Liquid-based cytology specimen preparation in the era of the COVID-19 pandemic: The experience of a laboratory in a Portuguese central hospital. Cancer Cytopathol. 2020 Dec; 128(12):913.
-
Liquid biopsy technologies for hematological diseases. Med Res Rev. 2021 01; 41(1):246-274.
-
Description of a new biosafe procedure for cytological specimens from patients with COVID-19 processed by liquid-based preparations. Cancer Cytopathol. 2020 Dec; 128(12):905-909.
-
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020 08; 8(2).